Tremtelectogene Empogeditemcel is a gene-modified cell therapy commercialized by Vor BioPharma, with a leading Phase II program in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Tremtelectogene Empogeditemcel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Tremtelectogene Empogeditemcel is expected to reach an annual total of $98 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Tremtelectogene Empogeditemcel Overview
Trem-cel (VOR-33) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndrome and myeloproliferative neoplasm . It is administered via parenteral route. The therapeutic candidate comprises allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC).It is developed based on eHSC technology.
Vor BioPharma Overview
Vor BioPharma (Vor Bio), a subsidiary of Puretech Health Plc, is a clinical-stage cell and genome engineering company that develops novel therapies for blood cancers. The company’s pipeline products include VCAR33 ALLO, VBP101, and VCAR33 for the indications of myelodysplastic syndromes and acute myeloid leukemia. It also leveraging its platform provides a CD33-CLL1 Treatment System. The company’s products are its proprietary treatment platform and its pipeline of therapies includes clinical trials for patients with relapsed and refractory Acute Myeloid Leukemia (AML). Vor Bio services are utilized by patients and caregivers, medical professionals, and investors in the biopharma sector. Vor Bio is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$126 million in FY2023, compared to an operating loss of US$93.4 million in FY2022. The net loss of the company was US$117.9 million in FY2023, compared to a net loss of US$92.1 million in FY2022.
For a complete picture of Tremtelectogene Empogeditemcel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
